This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Study Presented at the 52nd ICAAC Validates Aganocide Compound's Mechanism of Action
EMERYVILLE, Calif., Sept. 12, 2012 (GLOBE NEWSWIRE) -- NovaBay
® Pharmaceuticals, Inc. (NYSE-MKT:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide
® compounds for the local non-systemic treatment and prevention of infections, announces data supporting the mechanism of action for its lead Aganocide compound, NVC-422, against toxins secreted by bacteria such as
Escherichia coli (
E. coli). The data was presented at the 52
nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, on September 12, 2012 in a poster that featured a collaborative study with the Innsbruck Medical University.
The poster, titled "
N-chlorotaurine, a long-lived endogenous oxidant, inactivates Shiga toxin 2 (Stx2) of enterohemorrhagic
E. coli" shows data from a study investigating the chemical impact of Aganocide compounds
N-chlorotaurine (NCT), a long-lived oxidant produced by the activation of human white blood cells and known to exert broad-spectrum antimicrobial activity, and its novel analog with long-term solution stability, NVC-422, on Shiga toxin 2 (Stx2), a toxin secreted by
E. coli. The study provided evidence that 5.5 mM of NCT or NVC-422 oxidizes and inactivates the toxin Stx2, therefore concluding that long-lived oxidants, such as NCT, may act as powerful tools of innate immunity against soluble toxins secreted by common bacteria.
Dmitri Debabov, Ph.D., Director of Cell Biology and Microbiology at NovaBay and co-author of the study, stated, "This study shows the chemical impact of Aganocides and proves their ability to neutralize bacterial toxins. With the discovery of NovaBay's Aganocide NVC-422, we've identified a novel analog of NCT with a higher long-term solution stability, rapid antimicrobial activity and activity against bacterial toxins. Therefore, we believe this data provides further evidence that NVC-422 is capable of therapeutic success as a topical anti-infective."